AVPR2 and autosomal dominant polycystic kidney disease: Tolvaptan and vasopressin V2-receptor antagonists are the therapeutic agents for ADPKD in adults; they slowed down the increase in TKV and the decline in kidney function over a three-year period in one study [13,14].